Establishment Labs Holdings Inc., a pioneer in medical technology focusing on women’s health, has pushed the envelope further by unveiling its 2025 Post-Market Surveillance (PMS) Report. This release, ahead of the American Society of Plastic Surgeons’ annual gathering, reflects a decade and a half of dedication to transparency and accountability, boasting a remarkably low less-than-1% complication rate with Motiva implants globally. With steadfast annual publication since 2010, the PMS report underscores the company’s resilience and continual growth, especially notable following FDA approval in the United States. The drive for consistent, high-quality outcomes reveals their leadership and transformative role within the industry.
Data-Driven Success
The recently published report provides an in-depth review of Motiva implants’ real-world performance, encapsulating data from scholarly articles, global registries, warranty claims, and regulatory approval studies. The sustained consistency in outcomes across various regions and methodologies accentuates the intentional design efforts driving Establishment Labs’ success. Chief Technology Officer, Roberto de Mezerville, emphasizes that the technological advancements have not only improved performance benchmarks but also set new standards for what women worldwide can expect from breast augmentation and reconstruction.
Driving Innovative Change
Beyond performance, Establishment Labs’ innovative drive unfolds with their proprietary solutions like Mia Femtech® for breast harmonization and Preservé™ technology, facilitating minimal invasiveness and preserving breast tissue. Their revolutionary approach includes the Motiva Flora® tissue expander with a cutting-edge radio-frequency integrated port, ensuring enhanced outcomes for breast cancer reconstruction.
Key inferences from the report reveal the operational strategies behind Establishment Labs’ growth trajectory:
- Sustained less-than-1% complication rates with Motiva implants.
- Annual release of comprehensive surveillance data since 2010.
- High confidence in continued financial growth following U.S. market introduction.
- Technological advancements redefining industry standards.
Their commitment to technological innovations and rigorous data collection has led to a significant transformation in breast aesthetics and reconstruction. By marrying science and engineering, the company has crafted solutions that continually impress surgeons and patients alike, emphasizing safety and satisfaction nationwide. As more women opt for these advanced procedures, the emphasis on minimally invasive techniques becomes a pivotal component of their successful uptake.
Reflecting on a future poised for even more revolutionary developments, stakeholders can expect Establishment Labs to offer cutting-edge solutions that remain at the forefront of the medical technology landscape. As evidenced by their ongoing growth and expansion efforts, the company remains a beacon for innovation driven by unwavering dedication to women’s health and advanced breast care solutions.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
